Haider is an entrepreneur, blending innovation, commercial and marketing leadership into brands. He is specialised on business transformation and product launches within regulated industries such as pharma. Haider Alleg is Global Head of Digital Excellence for Ferring Pharmaceuticals.
Developing a natural obsession for creating new customer experiences, Haider disrupts the way global organisations adopt new marketing and technology trends. He is inspired by Japanese methodologies (Kaizen and Lean 6 Sigma) and adapts them to commercial operations to scale their business models globally.
Entrepreneur, he founded his first company at 16 in the East of France, specialised in political campaigns and social media. In 2013 he founded one of the fastest-growing consulting and venture firms in Switzerland, supporting companies like PregLem SA, sold to Gedeon Richter for 500M€. In 2015, he founded the Swiss hub of the French Tech initiative, created by the French President Emmanuel Macron.
Feel free to follow him on his Twitter account (@Haider_Alleg).
Antoine has been involved with Startups as a coach, consultant, trainer, investor, advisor on fundraising for over 10 years, with a fair degree of success as measured by their progress. Before that, he had accumulated a rare experience as a global investor in Equities and Private Equity with Capital Group, one of the best firms in the business, continuously visiting companies around the world in a high-paced environment. As a result he has a great flair for business models of all kinds and in all geographies, for management teams, their potential to create value – and thus can help you best understand investors' expectations, and how to pitch to them.
He is at his best helping companies, in a challenging but friendly and constructive style, to best align their project with their core skills, chose which markets to focus on and why, fine-tune their product strategy, develop a solid financial model. Aside from work, Antoine is a keen long-distance open water swimmer, an enthusiastic mountaineer, a solid amateur singer, and a writer.
Startup coach by vocation, accredited by 7 organizations of the entrepreneurial ecosystem, Caroline is also an entrepreneur & illustrator.
She helps you achieve your goals & exceed them if you wish, by revealing & enhancing skills for your projects, using her extended experience in the fields she has practical experience in, notably ICT & digital & data, as well as specific tools & her network.
Startups appreciate her involvement as a sparring partner, pragmatic approach and capacity to inspire them & develop their projects & skills. Some examples of topics achieved for early stage startups: consolidate who you target, your revenue model, setup your financials, enhance your pitch & pitching skills, next steps in the entrepreneurial ecosystem.
Feel free to discover amazing personalities coached overs 6 months (50+) and their recommendations on: https://ideix.io/startups/.
Tanja Dowe is the CEO of Debiopharm Innovation Fund, the digital health investment arm of Debiopharm located in Lausanne, Switzerland. Passionate about transforming healthcare and pharmaceutical development through digital innovation, Tanja is constantly on the look for ambitious entrepreneurs who do not settle for status quo. During her 20 year career as an entrepreneur and international transaction & strategy consultant at Innomedica before joining Debiopharm, she worked with more than 80 medical & healthcare companies globally, giving her a broad view into product development, team building and commercial strategies that work - and some that don't. Tanja is an experienced board member and chairwoman with a track record of successful M&A exits. MSc Tech in Applied Microbiology and Biochemistry from Helsinki University of Technology.
Marta is a business development and marketing strategist with track record in Biotech and Medical Devices with leading multinationals and young innovators.
Following a career in marketing and commercial operations with Merck-Serono and then Medtronic, Marta has worked in woman’s health, ophthalmology, headache, hypertension, heart failure, orthobiologics, GI disease, neuropathic pain, biomarkers, digital health and the active implantables space.
Marta has extensive experience working with young innovators to bring their technologies to market. She is member of the Program Management Committee of the School for Biomedical Entrepreneurship (SITEM) of the University of Bern. where she teaches Innovation and medical marketing and sales. She also serves as Western Switzerland Liaison for the Swiss Biotech Association and is a trainer with Innosuisse at the EPFL Innovation Park.
Emi is an entrepreneur, running-enthusiast, investor and world traveler based in Boston. Prior to Joyance, she founded a diabetes digital health company, worked for Half Court Ventures, an early-stage VC firm, and was the Director for Harvard’s premier undergraduate competition, i3 Innovation Challenge. She holds a BA in Molecular Biology from Harvard College and is a co-author in two publications related to cardiovascular regeneration in Circulation Research and Nature Communications. At Joyance, she focuses on biotech and healthcare investments. Emi is passionate about health equity and helping founders accomplish their goals.
Nanci Govinder is a business angel investor, board member, executive coach, entrepreneurship trainer and a strategic advisor to startups and accelerators. She has worked for more than 20 years in medical device companies (Johnson & Johnson; Medtronic) as Senior Research Scientisit, Director of Marketing and Business Unit Manager. She then transitioned to startups as CEO for two companies and as a board member and investor. She was also the Head Coach for the Swiss Federal Innovation Promotion Agency, managing 20 business coaches and evaluating and supporting > 100 deep tech startup companies. She is a highly experienced business angel investor with a portfolio of >25 companies and two exits and was the Deal Leader, Switzerland, for Rising Tide Europe, a group of 270 women business angels across Europe.
Nanci also founded a local branch of the Healthcare Businesswomen’s Association (HBA), an international organization developing and promoting female thought leaders in the healthcare industry. She was a member of the European Board and a mentor.
Nanci has a B.Sc. degree in Chemistry and Applied Chemistry; a B.Sc. degree from the American Institute of Holistic Theology; an MBA; and a diploma in Corporate and Business Coaching.
Doug tries to help innovators deliver on their ideas through connecting them to knowledge, challenge and questions, structure and supporters. He most recently worked to develop and run the DayOne Accelerator for Digital Health solutions based in Basel. Doug helped to co-found the DayOne initiative for Healthcare Innovation that brings together healthcare innovators from Healthcare Providers, Pharma, Academia and startups.
Prior to this he had a career advising companies and start-ups in healthcare, financial services, engineering and media. He spent five years in a Fintech start-up and has also worked in Drug Development with a big Pharma company. He grew up in Australia and has worked in Australia, the United Kingdom, Sweden and Switzerland.
Reto has been is Business Coach at EPFL Innovation Park for the last14 years and is coaching many companies in the lifescience, BioTech, MedTech, B2B fields. He knows what it means to lead a start-up as he was Chairman of DistalMotion for 5+ years and he can pass on his experience on the following topics: business plans, sales & marketing, industrial partnerships, business and product development.
Educated at the University of Massachusetts Amherst, USA.
Susan Herbert is the Global Head of Marketing and Strategy Operations at Merck. In this role she has overall accountability for Strategic Planning and Portfolio Management, Strategic Insights, Marketing Excellence including Brand Planning, launch excellence, launch planning and the Digital Excellence for Healthcare. She has extensive leadership experience across a variety of roles in Pharma Manufacturing, R&D and Portfolio Development. During her career she has led teams responsible for strategic business insights and forecasting, strategy development, program and product development, and most recently, she served as the Head of Global Business Development and Alliance Management within the Biopharma business of Merck. She has a PhD in Biochemistry and is based in Switzerla
Forward-thinking high performing business development professional who consistently outperforms expectations.
Successful track record in sourcing business development opportunities, deal negotiations, and closures from discovery to development stage opportunities, including academic partnerships and collaborations.
Recognized as a biopharmaceutical business development professional experienced with a diverse portfolio of transactions including discovery/research collaborations, co-development/co-promote arrangements, licensing (in/out), M&A, divestitures/spin-outs, option deals, and asset deals (buy/sell).
Proficient in communicating and engaging with C-level executives to accomplish goals and objectives. Skilled in spearheading strategic change management processes/initiatives in the company (both in R&D, commercial operation, and overall company direction).
Claude Joris, Secretary General of the world‘s most diversified and dynamic Life Science Cluster « BioAlps » is responsiblefor the promotion of the excellence and the performance of all life sciencesactors from Western Switzerland locally, nationwide and in the internationalarena.
He has an extensive experience in R&D, marketing, sales customer services andgeneral management. He gained those experiences in Switzerland but also as an expatliving in 8 different countries located in North America, Europe and Asia. Hedeveloped sales and marketing business activities and travelled in 82 countries.He contributed to the development and the growth of 7 swiss innovative tech start-upsusing his managerial and scientific competencies.
He worked for blue-chip companies: Capital Investment Ventures in Europe andUSA, Schlumberger, GoodYear Aircraft Engineering, Hach Ultra Analytics, Tornos,Usines Metallurgies de Vallorbe and small Startups.
His professional experiences cover a large spectrum of industrial and R&Ddomains: aerospace, oil and gas, investments, semi-conductor, pharmaceutical,biotech, medtech, healthcare, chemical, food, nuclear and fossil fuel power plants,water treatment plant, beverage, automotive, FMCG and scientific researchprojects.
He holds two university master degrees in civil engineering (PolytechnicUniversity) and business management (MBA). Multicultural, Swiss citizen, healso wrote and contributed to several scientific papers, articles for the generalpublic, specialized magazines and gave lecturers at several universities acrossall continents.
Pascal started his professional career at McKinsey, after studies at the University of St. Gallen and Columbia Business School. Over the last 20 years he built three startups in the healthcare space – the latest being Ava. And successfully raised ten financing rounds – from USD 100k to USD 30m – with investors from all over the world. Pascal currently lives in Zurich, and spends substantial time in San Francisco, Shenzhen and other tech centers around the world.
Nicolas Loeillot is a senior technology entrepreneur and investor.
Back in 2003, he founded a computer vision company in Japan. Pioneering in A.I. applications, his company served hundreds of projects with large companies in Japan, Asia and the US before being acquired by a GAFA in 2017. Since 2010, he chairs the Tokyo Interaction Center, a privately-owned incubator in central Tokyo, focused on early stage deep technologies.
In 2018, Nicolas Loeillot joined the Swiss health insurer Groupe Mutuel as Chief Innovation Officer to set up an innovation strategy, accelerate deployments of A.I. and craft a data-driven, prevention-focused future of the company. In 2021 he joins InnoSuisse as Expert for a 4-year mandat
Healthcare executive with over 20 years’ experience. Ksenija is currently the CEO of ex-Sofinnova portfolio company PregLem SA, a reproductive health pharma company based in Geneva. She also works as an operational investor at JEITO Investment fund. She joined PregLem at inception late 2007 as one of the early members of the team, initially led business development and marketing and then became CCO and CEO. During her tenure, she led the negotiations of several licensing deals which expanded PregLem’s portfolio and was instrumental in developing cumulative sales of over €260mn within five years of drug launch. Ksenija also led, for PregLem, the negotiations for the company’s sale to Gedeon Richer for CHF445 mn(€337mn).
Prior to PregLem, Ksenija worked for seven years with Serono (then Merck Serono) in sales and marketing.
Ksenija has frequently acted as operational advisor to venture capital, including Sofinnova Partners.
Bio Marco Rüedi, MD, eMBA, eMMM
Marco is Entrepreneur, Coach and Trainer in the Swiss Start-up ecosystem with 20+ years international experience in strategic and operational roles across the LifeScience Industry and Healthcare Management.
He is a strong believer in well-balanced teams: motivated to challenge the status quo!
Passionate to work with the next generation of Entrepreneurs/Managers for the challenges of tomorrow. He focused on Start-up and Innovation Management, Translational medicine. His motto is “From idea to market”.
He holds a Medical Doctor from the University of Fribourg, Berne and Zurich, an Executive Masters in Medical Management from eMMM PHW Bern, and an Executive Masters in Business Administration from eMBA PHW Bern.
Martin Velasco is an entrepreneur and Business Angel with extensive experience in the IT, medical and biotech areas.
He is the Founder, Chairman and CEO of Anecova, an assisted reproductive technology (ART) company and World Economic Forum Technology Pioneer 2008. He serves on the board/advisory board of several high-tech companies including: AC-Immune, a leader in Alzheimer's and neurodegenerative diseases drug development and World Economic Forum Technology Pioneer 2009, as Vice Chairman; Aridhia, a Health Informatics company, as Board Member and Cocomore, a digital communications agency & IT services firm, as Chairman of the Supervisory Board. Martin is also the Founder of Infantia Foundation, a philanthropic organisation aiding children in the developing world. He is Member of the Fondation EPFL Innovation Park and member of the Strategic Advisory Board at the Ecole Polytechnique Fédérale de Lausanne (EPFL).
Lan is the Deputy Managing Director of EPFL Innovation Park and an Expert of Innosuisse – the Swiss Innovation Agency. She has 23years of hands-on professional experience in industry as well as in the ecosystem of innovation & entrepreneurship.
Lan started her career at R&D department of Rolex, in charge of creating new computer aided design and optimisation tools in the product development process. She was later appointed as Head of Operational Planning at Pictet, working closely with a startup to design, develop and implement a management information system for group operation control. As the Managing Director of Geneva Creativity Center, she connected large corporations, SMEs, startups and researchers to initiate innovative joint R&D projects.
Currently at EPFL Innovation Park, she is leading entrepreneurship training and acceleration programs and is helping startups to establish business partnership with large corporations. Lan has a PhD degree from EPFL, an MBA from HEC Lausanne and postdoctoral applied research experience at Stanford University.
Jean spent over 20 years in technology oriented companies. His domains of expertise range from international sales to management of IT telecom businesses and company organisation. While an executive in large multinational companies, he experienced many of the domestic and international development stages of a corporation. Jean is also an entrepreneur and started several ventures which have been successfully sold. Jean is currently a chairman or board member of several small and medium-sized companies and start-ups. He also acts as a lecturer for institutions like UNIL, RCE, Board Academy and ZHAW and advises entrepreneurs and SMEs for Innosuisse and Innovaud.
Raymon uit de Bulten is an experienced and results-driven leader in new proposition and business creation at Philips. As Director Start-up Ventures he leads a team of cross-functional intrapreneurs in developing new solutions and business models via internal ventures and incubators. Outward looking, creative and forward-thinking; Raymon specializes in bringing together business opportunities, innovation and design to create meaningful consumer solutions.
“We’re here to put a dent in the universe. Otherwise, why even be here?” Steve Jobs tweeted that in 1985 (well he said it in an interview, these were the 80’s). Meet Jeroen van den Oever, leading finance and operations at SUN bioscience, the Organoid company. Straight talking Dutch financial expert trying to make a remarkable difference in the world around us. Equipped with a wicked sense of humour and a hunger to challenge the status quo he is out to improve drug development through innovation and entrepreneurship.
Founder of a regulatory technology start-up (sold in 2010) he converted an early technology project into a viable business with clients in the corporate world. Wanting to pay forward what he had learnt Jeroen started sharing his experience with start-ups and corporates alike. Jeroen’s talent was spotted at SUN bioscience that offered him the opportunity to join the company and never be bored again.
Jeroen is a licensed CPA and experienced board member. He learnt the trade in the first 12 years of his career at KPMG. For inquiries reach out to him on LinkedIn.